UsAgainstAlzheimer’s Calls Biogen Submission of Alzheimer’s Treatment for FDA Review and Approval an Exciting Step Forward
WASHINGTON, DC (July 8, 2020) – George Vradenburg, chairman and co-founder of UsAgainstAlzheimer’s, issued the following statement on the announcement today that Biogen has completed its filing of the Biologics License Application to the Food and Drug Administration (FDA) for regulatory review and approval of aducanumab, a treatment for early stage Alzheimer’s disease. Clinical studies have shown aducanumab can slow the decline in some patients with early Alzheimer’s disease.
“This filing is an exciting and important step toward what could become the first therapy to modify the course of Alzheimer’s disease.
“We urge the FDA to conduct an expeditious and rigorous assessment of the safety and efficacy of this drug.
“If approved, this drug would enable people with early stage Alzheimer’s to live with a higher quality of life for a longer period of time. Approval also would accelerate drug development and stimulate further investment of therapies and treatments throughout the pipeline and would represent a real turning point in the efforts to stop Alzheimer’s disease.”